Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine
- Authors
- Huh Kyungmin; Na Yewon; Kim Young-Eun; Radnaabaatar Munkhzul; Peck Kyong Ran; Jung Jaehun
- Issue Date
- Jul-2021
- Publisher
- 대한의학회
- Keywords
- COVID-19; Thrombosis with Thrombocytopenia Syndrome; Vaccination; Vaccine Adverse Events
- Citation
- Journal of Korean Medical Science, v.36, no.27, pp.1 - 6
- Journal Title
- Journal of Korean Medical Science
- Volume
- 36
- Number
- 27
- Start Page
- 1
- End Page
- 6
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81749
- DOI
- 10.3346/jkms.2021.36.e197
- ISSN
- 1011-8934
- Abstract
- We used the nationwide claims database to calculate the incidence of thrombotic events and predict their overall 2-week incidence. From 2006 to 2020, the incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC) tended to increase. Unlike intracranial venous thrombosis (ICVT) and intracranial thrombophlebitis (ICTP), which showed no age difference, other venous embolism, and thrombosis (OVET), DIC, DVT, and PE were significantly more common in over 65 years.
The overall 2-week incidence of ICVT was 0.21/1,000,000 (95% confidence interval [CI], 0.11–0.32). ICTP, OVET, DIC, DVT and PE were expected to occur in 0.08 (95% CI, 0.02– 0.14), 7.66 (95% CI, 6.08–9.23), 5.95 (95% CI, 4.88–7.03), 13.28 (95% CI, 11.92–14.64), 14.09 (95% CI, 12.80–15.37) per 1,000,000, respectively. To date, of 8,548,231 patients vaccinated with ChAdOx1 nCoV-19 in Korea, two had confirmed thrombosis with thrombocytopenia syndrome within 2 weeks. The observed incidence of ICVT after vaccination was 0.23/1,000,000.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81749)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.